Radiopharmaceuticals in PET Imaging Market Size is valued at USD 1.56 Bn in 2024 and is predicted to reach USD 3.02 Bn by the year 2034 at a 7.1% CAGR during the forecast period for 2025-2034.
In medical imaging, Positron Emission Tomography (PET) has emerged as a key technique for the diagnosis and treatment of a number of illnesses, most notably cancer, neurological disorders, and cardiovascular ailments. Radiopharmaceuticals, which are radioactive substances used as tracers to see biological processes in vivo, are essential to the success of PET imaging. The market for these goods is expanding quickly because of developments in PET technology and the creation of novel radiopharmaceuticals.
The growing need for early illness detection, especially for cancer and neurological disorders, is fueling the global market for radiopharmaceuticals in PET imaging. Radiopharmaceuticals aid in tumour detection, therapy effectiveness monitoring, and organ metabolic function evaluation. The market for radiopharmaceuticals in PET imaging is poised for substantial development due to ongoing technical advancements, rising healthcare spending, and growing precision medicine applications.
In addition, to visualize brain activity and identify neurological conditions, including epilepsy, Parkinson's disease, and Alzheimer's disease, radiopharmaceuticals are crucial. The radiopharmaceuticals in the PET imaging market is expanding because of the growing need for neurological PET imaging and the ageing population.
The Radiopharmaceuticals in PET Imaging market is segmented based on Radioisotope Type, Application, and End-user. Based on radioisotope type, the market is segmented into F-18 (F-18 FDG, F-18 Fiorbetapir, F-18 Fiobetaben, F-18 Sodium Fluoride, and Others), Rb-82, G-68, and Other PET Isotopes. The applicaiton segment comprises Oncology (Lung Cancer, Breast Cancer, Others), Cardiology, Neurology (Dementia, Parkinson's Disease, Others), and Others. By end-user, the segmentation includes Hospitals and Clinics, Medical Imaging Centers, and Other End-users.
The F-18 Sodium Fluoride category is expected to hold a major global market share in 2021 driven by its growing use in cancer and bone scanning applications. When compared to traditional technetium-based bone scans, F-18 NaF is a highly effective PET radiotracer for detecting bone metastases, providing better imaging quality and faster uptake. The market for F-18 NaF has increased as a result of the increased demand for more accurate diagnostic tools brought on by the rising incidence of cancer, especially breast and prostate cancer. Developments in technology and growing provider awareness of the advantages of early and precise bone disease detection are also accelerating PET/CT use.
The increasing global existance of cancer and the growing need for accurate and early tumour identification are driving the expansion of the oncology sector in the market for radiopharmaceuticals for PET imaging. F-18 Fluorodeoxyglucose (FDG) and F-18 Sodium Fluoride (NaF) are two examples of PET radiopharmaceuticals that are essential for cancer diagnosis, staging, treatment planning, and therapy response monitoring. Technological developments have significantly improved the precision and therapeutic usefulness of PET imaging in oncology in hybrid imaging systems.
The North American Radiopharmaceuticals in PET Imaging market is expected to register the highest market share in revenue in the near future. In North America, cancer and neurological conditions, including Parkinson's, Alzheimer's, and other dementias, are becoming more common. In neurology and cancer, PET imaging is an essential tool, especially for continuing monitoring, therapy planning, and early discovery. This tendency is anticipated to continue as the population ages, increasing the need for radiopharmaceuticals in PET. In addition, Europe is projected to grow rapidly in the global Radiopharmaceuticals in PET Imaging market.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.54 Bn |
|
Market Size Value in 2034 |
USD 3.02 Bn |
|
Growth Rate CAGR |
CAGR of 7.1% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2024-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Radioisotope Type, Application, and End-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia |
|
Competitive Landscape |
Curium, Telix Pharmaceuticals, Lantheus Holdings, Inc., GE Healthcare, Life Molecular Imaging, Siemens Healthineers, Avid Radiopharmaceuticals, Cardinal Health, Eckert & Ziegler. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceuticals in PET Imaging Market Snapshot
Chapter 4. Global Radiopharmaceuticals in PET Imaging Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on Radiopharmaceuticals in PET Imaging Market Industry Trends
4.10. Global Radiopharmaceuticals in PET Imaging Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Radiopharmaceuticals in PET Imaging Market Segmentation 1: By Radioisotope Type, Estimates & Trend Analysis
5.1. Market Share by Radioisotope Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Radioisotope Type:
5.2.1. F-18
5.2.1.1. F-18 FDG
5.2.1.2. F-18 Fiorbetapir
5.2.1.3. F-18 Fiobetaben
5.2.1.4. F-18 Sodium Fluoride
5.2.1.5. Others
5.2.2. Rb-82
5.2.3. G-68
5.2.4. Other PET Isotopes
Chapter 6. Radiopharmaceuticals in PET Imaging Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Oncology
6.2.1.1. Lung Cancer
6.2.1.2. Breast Cancer
6.2.1.3. Others
6.2.2. Cardiology
6.2.3. Neurology
6.2.3.1. Dementia
6.2.3.2. Parkinson's Disease
6.2.3.3. Others
6.2.4. Others
Chapter 7. Radiopharmaceuticals in PET Imaging Market Segmentation 3: By End User, Estimates & Trend Analysis
7.1. Market Share by End User, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
7.2.1. Hospitals and Clinics
7.2.2. Medical Imaging Centers
7.2.3. Other End Users
Chapter 8. Radiopharmaceuticals in PET Imaging Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Radiopharmaceuticals in PET Imaging Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope Type, 2021-2034
8.2.3. North America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.3. Europe
8.3.1. Europe Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope Type, 2021-2034
8.3.3. Europe Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Southeast Asia
8.4.1.7. Rest of Asia Pacific
8.4.2. Asia Pacific Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope Type, 2021-2034
8.4.3. Asia Pacific Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.5. Latin America
8.5.1. Latin America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope Type, 2021-2034
8.5.3. Latin America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. South Africa
8.6.1.3. Rest of Middle East and Africa
8.6.2. Middle East & Africa Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope Type, 2021-2034
8.6.3. Middle East & Africa Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa Radiopharmaceuticals in PET Imaging Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Curium
9.2.2. Telix Pharmaceuticals
9.2.3. Lantheus Holdings, Inc.
9.2.4. GE Healthcare
9.2.5. Life Molecular Imaging
9.2.6. Siemens Healthineers
9.2.7. Avid Radiopharmaceuticals
9.2.8. Cardinal Health
9.2.9. Eckert & Ziegler
Radiopharmaceuticals in PET Imaging Market By Application-
Radiopharmaceuticals in PET Imaging Market By End-User-
Radiopharmaceuticals in PET Imaging Market By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
